Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): a Subgroup Analysis of GRIFFIN (AFT-29)
- Citation:
- Blood vol 138 (Supplement 1) 2723
- Meeting Instance:
- ASH 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- AFT
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3854
- Pharmas:
- JNJ
- Grants:
- Corr. Author:
- Authors:
- Larry D. Anderson Jr. Jonathan L. Kaufman Jacob Laubach Douglas W. Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J. Costa Nitya Nathwani Nina Shah Naresh Bumma Sarah A. Holstein Caitlin Costello Andrzej Jakubowiak Tanya M. Wildes Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Huiling Pei Annelore Cortoos Sharmila Patel Blake Bartlett Jessica Vermeulen Thomas S. Lin Peter M. Voorhees Paul G. Richardson
- Networks:
- CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, OR013
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: